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Introduction
Dyes that were shown to demonstrate bacteria in the presence of mammalian cells were the progenitors of modern chemotherapeutic agents. Work by Gram, Koch, Ehrlich and others provided a sound basis for the idea of selective toxicity, and several biological stains were introduced as antimicrobial agents in the early part of the last century, namely the acridines proflavine and acriflavine against bacterial infection and the triphenylmethanes crystal violet and brilliant green against both bacterial and fungal infection [1] . Whilst the use of such agents caused tissue staining, many lives were saved, for example during the First World War where 'flavine therapy' was employed in battlefield injuries [2] . Agents such as the acridine dye acriflavine were also tested as systemic (oral) preparations for gonorrhoea, the highly hydrophilic nature of the dye ensuring rapid elimination [3] .
Whilst the use of dyes in antimicrobial chemotherapy was naturally cut short by the emergence of penicillin and the modern antibacterials, the use of colour in tissue differentiation has never significantly decreased. Intraoperative use of stains such as methylene blue normally employs aqueous solutions of the dye at typical concentrations of 1% w/v [4] . This concentration of methylene blue (intravenous) is also indicated for the treatment of methaemoglobinaemia, both uses thus demonstrating the low toxicity associated with the phenothiazine derivative. From an antimicrobial point of view, methylene blue has also been administered in the treatment of juvenile falciparum malaria in a significant trial in Burkina Faso [5] , whilst the related Photodynamic agents, or photosensitisers, use light energy to promote the formation of reactive oxygen species (ROS) such as singlet oxygen, superoxide, hydroxyl radicals etc. in situ (Fig. 1) . Such species represent a considerable toxic threat to simple microbial cells.
Photoantimicrobials
As noted above, there are various dyes that pre-date conventional drugs as antimicrobials. Since the first literature report of photoantimicrobial action was published in 1900, this too has a longer history [7] . However, for the reasons mentioned previously, photoantimicrobial agents, which were also dyes, were M a n u s c r i p t Plainly, the level of investment made by the pharmaceutical industry in developing antimicrobial chemotherapeutics is enormous. Consequently, the sites and modes of action of modern agents are understood in exquisite detail; indeed, such is the level of understanding that for several decades drug molecules have been specifically designed to be target-specific. As noted in the introduction, this degree of sophistication, while allowing targeting at the molecular level, also exerts selective pressure and promotes microbial resistance development.
Photoantimicrobial agents are not single-target specific. Production of highly reactive singlet oxygen in situ means that a range of biomolecular targets is available in the immediate environment of the photosensitiser (structural proteins, enzymes, nucleic acids, unsaturated lipids etc.) via the diffusion of ROS. Consequently, activity against conventional drug-susceptible microbes is also observed for strains that are conventional-resistant [8, 9] . Multiple sites of therapeutic action can be achieved by employing combinations of conventional drugs, as already mentioned, but again this is based on defined, rather than variable, sites of action. In addition, the practicalities of combining different drugs may be self-defeating (drug-drug interactions, contraindication, formulation etc. and, of course, cost).
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As an example, the standard photosensitiser methylene blue has been shown to cause photodamage in the Gram-negative organism Escherichia coli at the level of the outer membrane [10] , cell wall [11] , ribosome [12] and nucleic acid [13] . To achieve such varied targeting with conventional agents would require the combination of, for example, a peptide antibiotic, a -lactam agent, a tetracycline and a fluoroquinolone. 
Permitted agents
The principal dye/photosensitiser in terms of human use is methylene blue, this compound having been employed in various applications, both indicative and therapeutic, since the late 19th century [14] . Other photosensitisers with everyday application in humans include the triphenylmethane dye gentian (crystal) violet and the food colourings erythrosine and phloxine B. Similarly, indocyanine green has various applications in clinical blood flow measurement M a n u s c r i p t [15] (see Table 1 ). Any or all of these examples could be utilised with relatively little difficulty from a regulatory point of view, since each is already in use in humans, and very seldom with any control of incident light. There are many newer, improved photosensitisers available as a result of two decades or more of concentrated research [16] , but these will require considerable investment in time and money in order to reach the clinic. Introduction of these improved agents will depend very much on acceptance of the 'standard' photosensitisers listed above.
The related anticancer approach employing photosensitisers is known as photodynamic therapy (PDT). The agents used here are porphyrin-basedhaematoporphyrin derivatives, chlorins or porphyrin precursors [17] . Whilst these are, happily, being increasingly licensed in specified cancers, their selectivity for microbial cells is limited and, consequently, they are not covered in this discussion.
Among the 'standard photosensitisers', the use of both methylene blue and crystal violet has been recounted above. Both erythrosine and phloxine B are globally accepted food colourings, whilst the former is also the staining constituent in dental plaque disclosing tablets. Conversely, indocyanine green, as well as being employed in blood volume/blood flow measurement, is a near-infrared absorber and has been shown to act photothermally in tissue soldering [18] (Table 1) . Product familiarity via clinicians' first-hand experience of these materials can only help to promote their use as photosensitisers.
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Photoantimicrobial activities
As indicated in Table 2 , both of the cationic (positively-charged) photosensitisers, methylene blue and crystal violet (Fig. 3) , are established broad-spectrum antimicrobials, i.e. active against all four major classes and subdivisions of microbial pathogens. The remaining agents in current human use are all associated with an overall anionic charge (Fig. 3) and this is established as a predisposing factor for lack of photobactericidal efficacy against Gram-negative organisms [19] .
It is evident from Table 2 that there is a considerable knowledge gap concerning erythrosine, phloxine B and indocyanine green with regard to active range. However, it has been reported that negatively-charged photosensitisers such as the related cyanine derivative merocyanine 540 are active against some viruses [20] . Similarly, since the two xanthene derivatives erythrosine and phloxine B have been reported to be effective against Grampositive oral pathogens such as Streptococcus mutans [21] , and indocyanine green is reportedly highly active against S. aureus and Streptococcus pyogenes [22] , this suggests their use against other Gram-positive organisms.
Erythrosine has also been reported to be toxic towards the yeast Saccharomyces cerevisiae [23] . Brief data for the compounds regarding both mammalian use/dose, in vitro photoantimicrobial activities and light dose are given in Table 1 . Reports of the use of photosensitisers in either human or animal infections are very scarce, although methylene blue has been used successfully (topical, 2% w/v, red light) in the treatment of onychomycosis [24] and in a murine model of oral candidiasis (local, 0.05% w/v, red light) [25] .
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Conclusion
Photosensitisers such as methylene blue and crystal violet have been shown to inactivate all of the bacterial species mentioned in the preceding paragraphs. Given the current state of knowledge regarding structure-activity relationships in photosensitisers, it would not be ridiculous to predict highly effective action against significant Gram-positive organisms for the remaining 'human-safe' photosensitisers covered here.
According to recent data, SSTIs constitute one-fifth of hospital-associated infections in England [26] . Given that many SSTIs offer relatively facile topical access, the use of photosensitisers here, in combination with superficial illumination, surely offers considerable potential for infection control. Such an approach has advantages both from the point of view of the lack of likely bacterial resistance and also in the resulting decrease in the use of conventional antimicrobial agents, thus allowing their conservation for more complicated or life-threatening systemic disease.
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